PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Share :
Published: 20 Sep 2021
Views: 2372
Dr Neal Shore and Prof Fred Saad

Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, USA) and Prof Fred Saad (University of Montreal Hospital Center, Montreal, Canada) discuss case based testing and clinical decisions regarding PARP inhibitors in prostate cancer.

Initially, they discuss testing for HRR deficiency in patients and the clinical decisions which follow such diagnosis.

They mention the types of testing available. Dr Shore then talks about integrating PARPi into the clinical pathway. Prof Saad shares his experience regarding when to test for this type of prostate cancer and how to test for it.

Dr Shore and Prof Saad also mention studies from AUA 2021 regarding PARPis for prostate cancer. They explain the use of NHAs for prostate cancer and discuss whether doctors should be using new hormonal agents (NHAs).

Prof Saad concludes by mentioning some of the AUA guidelines regarding testing for BRCA mutations and use of PARPis for prostate cancer.

This programme has been supported by an unrestricted educational grant from AstraZeneca.